{
    "2019-10-10": [
        [
            {
                "time": "2023-10-05",
                "original_text": "bluebird Inks Genome Editing Research Deal With Novo Nordisk",
                "features": {
                    "keywords": [
                        "bluebird",
                        "Genome Editing",
                        "Research Deal",
                        "Novo Nordisk"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2023-10-05",
                "original_text": "Is Novo Nordisk A/S (NVO) A Good Stock To Buy?",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "Good Stock",
                        "Buy"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}